| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuan Gao, Yun-Yi Gao, Rong-Ya Shi, Dong Ji, Yu Wang, Liang Xu, Qi Wang, Meng-Hua Wu, Han-Lu You, Qiu-Shi Bu, Yi-Xi Dong, Long-Zhen Zhou, Wei Liu, Qing-Kun Song, Ying Han, Hou Wei, Xin-Yu Zhang and Zhong-Jie Hu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support |
ZLRK202533 |
| High-Level Public Health Technology Talent Project |
2022-2-005 |
|
| Corresponding Author |
Zhong-Jie Hu, Chief Physician, Professor, Senior Researcher, Senior Scientist, Vice General Manager, Department of Liver Disease Center, Beijing You’an Hospital, Capital Medical University, No. 8 Xitoutiao outside You’anmen, Fengtai District, Beijing 100069, China. yfcyt@139.com |
| Key Words |
Sodium-glucose co-transporter 2 inhibitor; Empagliflozin; Cirrhosis; Ascites; Fractional excretion of sodium |
| Core Tip |
Refractory ascites reflects proximal tubular sodium retention and frequent diuretic resistance in cirrhosis. We present a multicenter randomized protocol testing empagliflozin, a sodium-glucose co-transporter 2 inhibitor that promotes proximal tubular natriuresis without renin-angiotensin-aldosterone system stimulation, for refractory cirrhotic ascites. The trial compares empagliflozin plus standard care versus standard care over 14 days. Primary endpoint is change in fractional excretion of sodium; secondary outcomes include 24-hour urinary sodium, urine volume, ascites by ultrasound, body weight, and prespecified clinical safety parameters. |
| Publish Date |
2025-10-27 10:57 |
| Citation |
<p>Gao Y, Gao YY, Shi RY, Ji D, Wang Y, Xu L, Wang Q, Wu MH, You HL, Bu QS, Dong YX, Zhou LZ, Liu W, Song QK, Han Y, Wei H, Zhang XY, Hu ZJ. Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites. <i>World J Hepatol</i> 2025; 17(10): 110247</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i10/110247.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i10.110247 |
